Review article: bifidobacteria as probiotic agents – physiological effects and clinical benefits

Alimentary Pharmacology and Therapeutics - Tập 22 Số 6 - Trang 495-512 - 2005
Céline Picard1, Jean Fioramonti2, Alan François1, Timothy P. Robinson1, Francoise Neant1, C Matuchansky3
1Danone Vitapole, Centre de Recherche Daniel Carasso, Nutrivaleur, Palaiseau, France
2Neurogastroenterology and Nutrition Unit, INRA, Toulouse, France
3Gastroenterology and Nutritional Support Service, Lariboisière University Hospital, Paris, France

Tóm tắt

Summary

Bifidobacteria, naturally present in the dominant colonic microbiota, represent up to 25% of the cultivable faecal bacteria in adults and 80% in infants. As probiotic agents, bifidobacteria have been studied for their efficacy in the prevention and treatment of a broad spectrum of animal and/or human gastrointestinal disorders, such as colonic transit disorders, intestinal infections, and colonic adenomas and cancer. The aim of this review is to focus on the gastrointestinal effects of bifidobacteria as probiotic agents in animal models and man. The traditional use of bifidobacteria in fermented dairy products and the GRAS (‘Generally Recognised As Safe’) status of certain strains attest to their safety. Some strains, especially Bifidobacterium animalis strain DN‐173 010 which has long been used in fermented dairy products, show high gastrointestinal survival capacity and exhibit probiotic properties in the colon. Bifidobacteria are able to prevent or alleviate infectious diarrhoea through their effects on the immune system and resistance to colonization by pathogens. There is some experimental evidence that certain bifidobacteria may actually protect the host from carcinogenic activity of intestinal flora. Bifidobacteria may exert protective intestinal actions through various mechanisms, and represent promising advances in the fields of prophylaxis and therapy.

Từ khóa


Tài liệu tham khảo

10.1016/S0140-6736(03)12489-0

10.1128/AEM.65.11.4799-4807.1999

Blaut M, 2002, Molecular biological methods for studying the gut microbiota: the EU human gut flora project, Br J Nutr, 87, S203, 10.1079/BJN/2002539

10.1128/AEM.67.10.4939-4942.2001

10.1128/AEM.70.1.167-173.2004

10.1128/AEM.70.12.7220-7228.2004

10.1079/BJN19980108

Yoshioka H, 1983, Development and differences of intestinal flora in the neonatal period in breast‐fed and bottle‐fed infants, Pediatrics, 72, 317, 10.1542/peds.72.3.317

10.1097/00005176-200001000-00019

10.1079/BJN/2002530

10.1093/ajcn/80.6.1658

10.1016/0168-1605(95)00067-T

10.1093/ajcn/73.2.465s

10.1111/j.1348-0421.2003.tb03464.x

10.1086/368080

10.1093/ajcn/73.2.365s

10.1111/j.1348-0421.1998.tb02337.x

European commission (Health and Consumer protection directorate‐general), Qualified Presumption of Safety. On a Generic Approach to the Safety Assessment of micro‐organisms Used in Feed/food and Feed/food Production

FAO/WHO, 2001, Report of a Joint FAO/WHO Expert Group. Health and Nutritional Properties of Probiotics in Food Including Powder milk with Live Lactic Acid Bacteria

10.1093/jn/125.6.1401

10.1093/ajcn/55.1.78

10.1016/0016-5085(92)90172-U

10.3168/jds.S0022-0302(91)78183-6

10.1093/ajcn/73.2.399s

10.1016/S0399-077X(05)80062-9

10.1046/j.1365-2672.2000.01073.x

Marteau P, 1992, Survival of Lactobacillus acidophilus and Bifidobacterium sp. in the small intestine following ingestion in fermented milk. A rational basis for the use of probiotics in man, Gastroenterol Clin Biol, 16, 25

10.1093/jn/127.1.89

10.1007/s12016-002-0011-0

10.12938/bifidus1996.20.43

10.1046/j.1365-2036.2002.01188.x

10.1080/08910600310015565

10.1080/089106001753341291

10.3109/00365529609094568

10.1146/annurev.nu.13.070193.001245

Boffa LC, 1992, Modulation of colonic epithelial cell proliferation, histone acetylation, and luminal short chain fatty acids by variation of dietary fiber (wheat bran) in rats, Cancer Res, 52, 5906

Cummings JH, 1995, Human Colonic Bacteria: Role in Nutrition, Physiology and Pathology, 101

10.1128/AEM.70.10.5810-5817.2004

10.1016/S0168-1605(02)00170-8

Krause LJ, 1996, Feeding human milk to rats increases Bifidobacterium in the cecum and colon which correlates with enhanced folate status, J Nutr, 126, 1505, 10.1093/jn/126.5.1505

10.1136/gut.47.5.646

10.1111/j.1365-2672.1994.tb03443.x

10.1128/AEM.63.2.506-512.1997

10.3168/jds.S0022-0302(95)76784-4

10.1007/BF02087647

10.1203/00006450-199406000-00014

10.12938/bifidus1982.10.1_19

Yamazaki S, 1985, Immunological responses to monoassociated Bifidobacterium longum and their relation to prevention of bacterial invasion, Immunology, 56, 43

10.12938/bifidus1982.7.2_71

10.1093/infdis/172.2.403

10.1016/0016-5085(89)90406-X

10.1111/j.1699-0463.1995.tb01073.x

10.1016/0016-5085(93)90436-G

Ouwehand A, 2002, The role of the intestinal microflora for the development of the immune system in early childhood, Eur J Nutr, 41, I32

10.1016/S1521-6918(03)00074-X

10.3168/jds.S0022-0302(95)76659-0

10.1093/ajcn/66.2.515S

10.3109/08923979209009228

Roos NM, 2000, Effects of probiotic bacteria on diarrhea, lipid metabolism, and carcinogenesis: a review of papers published between 1988 and 1998, Am J Clin Nutr, 71, 405, 10.1093/ajcn/71.2.405

Moreau MC, 1998, Functional Foods: The Consumer, the Products and the Evidence, 47

Moreau MC, 1998, International Congress of Immunology, 407

10.1016/S0140-6736(94)91708-6

Phuapradit P, 1999, Reduction of rotavirus infection in children receiving bifidobacteria‐supplemented formula, J Med Assoc Thai, 82, S43

10.1097/00005176-200403000-00011

10.1097/00005176-200403000-00011

10.1128/JCM.27.10.2328-2330.1989

10.1128/mr.59.2.171-200.1995

10.1016/S1590-8658(02)80171-2

10.1093/jac/46.4.603

Plummer S, 2004, Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea, Int Microbiol, 7, 59

10.1111/j.1365-2036.2004.02051.x

10.1053/j.gastro.2004.03.024

10.1053/gast.2000.9370

10.1136/gut.53.1.108

10.1016/S0016-5085(03)00171-9

10.1080/00365520410009339

10.1080/07315724.2003.10719276

10.1111/j.1365-2036.2004.02268.x

10.1136/gut.2004.044834

10.1080/089106001753341282

10.1053/j.gastro.2004.11.050

10.1038/scientificamerican0996-80

10.1093/carcin/23.3.477

10.1093/jnci/64.2.255

10.3109/07853899009147240

Ling WH, 1994, Lactobacillus strain GG supplementation decreases colonic hydrolytic and reductive enzyme activities in healthy female adults, J Nutr, 124, 18, 10.1093/jn/124.1.18

10.1093/ajcn/52.4.685

Pedrosa MC, 1995, Survival of yogurt‐containing organisms and Lactobacillus gasseri (ADH) and their effect on bacterial enzyme activity in the gastrointestinal tract of healthy and hypochlorhydric elderly subjects, Am J Clin Nutr, 61, 353, 10.1093/ajcn/61.2.353

10.1007/s00394-004-1203-6

10.1080/02652039009373938

10.1080/01635589009514073

Rowland IR, 1975, Degradation of N‐nitrosamines by intestinal bacteria, Appl Microbiol, 29, 7, 10.1128/am.29.1.7-12.1975

10.1016/0027-5107(94)90182-1

10.1207/s15327914nc4901_3

Bouhnik Y, 1996, Effects of Bifidobacterium sp fermented milk ingested with or without inulin on colonic bifidobacteria and enzymatic activities in healthy humans, Eur J Clin Nutr, 50, 269

Andrieux CM, 2002, Metabolic characteristics of the faecal microflora in humans from three age groups, Scand J Gastroenterol, 37, 792, 10.1080/gas.37.7.792.798

Ayanaba A, 1973, Microbial formation of nitrosamines in vitro, Appl Microbiol, 25, 862, 10.1128/am.25.6.862-868.1973

10.1017/S002202990200540X

10.1111/j.1472-765X.1995.tb00456.x

10.1111/j.1699-0463.1967.tb05183.x

10.1007/BF00294629

10.3168/jds.S0022-0302(99)75506-2

10.1093/jn/130.2.410S

10.1079/BJN20041386

10.1080/00365520410003515

Roncucci L, 1992, Early events in human colorectal carcinogenesis. Aberrant crypts and microadenoma, Ital J Gastroenterol, 24, 498

10.3168/jds.S0022-0302(96)76331-2

10.1080/01635589509514400

10.1016/0027-5107(95)00059-R

10.1017/S0022029900028478

10.1093/carcin/18.3.517

10.1093/jn/126.5.1362

10.1080/01635589609514492

10.1093/jn/129.1.77

Reddy BS, 1993, Inhibitory effect of Bifidobacterium longum on colon, mammary, and liver carcinogenesis induced by 2‐amino‐3‐methylimidazo[4,5‐f]quinoline, a food mutagen, Cancer Res, 53, 3914

10.1093/carcin/18.4.833

10.3181/00379727-207-43817

10.1093/carcin/16.2.245

10.1099/00207713-51-5-1633

10.1079/BJN20041289

10.1128/AEM.70.4.1923-1930.2004